Nilotinib
| Generic name | Nilotinib |
| Pronunciation | ny-LOH-ti-nib |
| Brand name(s), other common name(s) | Tasigna® |
| Drug type | Tyrosine kinase inhibitor |
| How the drug is given | By mouth |
Nilotinib is FDA approved to treat people who have Philadelphia-chromosome-positive chronic myeloid leukemia in adult patients whose disease could not be treated successfully with other therapies including imatinib (Gleevec®) or who cannot take imatinib.
Side effects needing medical attention:
Irregularity in heartbeat; fainting; unexplained bleeding or bruising; blood in urine or stool; unexplained weakness; yellow skin and eyes; shortness of breath; swelling of hands, ankles, feet, or face; sudden stomach area pain with nausea and vomiting; low blood count; rash; nausea; headache; itching; tiredness; diarrhea; constipation.
For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.
